Stimvia

Stimvia operates at the intersection of medical devices, digital health and therapeutic neuromodulation. Its primary market position is built around URIS®, a Class IIa device designed for non-invasive treatment of overactive bladder symptoms and lower urinary tract symptoms. The product combines electrical transcutaneous nerve modulation, percutaneous tibial nerve stimulation, remote treatment monitoring and AI-supported personalization. This creates a differentiated proposition relative to conventional symptom-management approaches by linking stimulation hardware with clinician feedback and treatment-data analysis. Stimvia’s commercial emphasis is becoming clearer: the May 2026 expansion of its scientific advisory board and commercial leadership, followed by Russ Mably’s appointment as CEO on Sep 29, 2026, points to a transition from technology and clinical development toward international commercialization. Its approximately $8.7 million in cumulative funding and 10 granted patents provide evidence of sustained development, but public information is limited on regulatory reach, revenue and adoption.

Stimvia’s growth trajectory shows a shift from technology creation toward international commercialization. The company has developed URIS®, a Class IIa medical device using non-invasive neuromodulation for overactive bladder symptoms, and has built an associated data layer for remote treatment monitoring, adaptive stimulation and predictive analytics. A notable inflection point came on May 13, 2026, when Stimvia announced expanded scientific advisory and commercial leadership capacity to advance global market expansion. The company also said it was strengthening its international commercial team and recruiting engineers and early-career talent. A second inflection point followed on Sep 29, 2026 with Russ Mably’s appointment as CEO to lead global growth and commercialization.